ZURICH, July 19 (Reuters) - Roche's Japanese subsidiary Chugai said on Tuesday subcutaneous injection of its Actemra drug has shown efficacy in rheumatoid arthritis compared to intravenous infusion.
Actemra (tocilizumab) is a prescription drug that’s used to treat certain conditions that affect your immune system. Actemra can cause side effects that range from mild to serious. Examples include ...
GenentechMedia:Joe St. Martin, 650-467-6800orInvestor:Thomas Kudsk Larsen, 650-467-2016Karl Mahler, 011 41 61 687 85 03 Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results